In people with HIV and MASLD who responded to semaglutide, twenty-four weeks of low-dose semaglutide improved MASLD severity by serum metabolomic profiling.
In plain wordsIn people with HIV and fatty liver disease who lost weight, twenty-four weeks of low-dose semaglutide improved a blood-based measure of liver disease severity.
- Peptide
- Semaglutide
- Outcome
- DecreaseMASLD severity by serum metabolomic profiling
- Study
n = 36
- Comparator
- Baseline
- Outcome group
- Liver fat and liver function · Liver
- Studied dose
- Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Twenty-four weeks of low-dose semaglutide led to significant improvement in MASLD disease severity by serum metabolomic profiling across all MASLD disease severity categories, suggesting histologic improvements.
2 context sentences(design, population, supporting numbers)
SLIM LIVER (ACTG A5371) was an open-label, phase 2b, single-arm trial of semaglutide in PWH and MASLD (2021-2022).
Adult participants who showed clinical response (>2.27 kg weight loss) to semaglutide during the study (N = 36) had their serum analysed for metabolomic profiling by the OWLiver® panel.